Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Atea Pharmaceuticals Advances HCV Phase 3 Program and Initiates HEV Phase 1

Atea Pharmaceuticals reported its first quarter 2026 financial results and provided a comprehensive business update, highlighting significant advancements in its Hepatitis C Virus (HCV) and Hepatitis E Virus (HEV) programs. The company's global Phase 3 program for HCV, evaluating the fixed-dose combination of bemnifosbuvir and ruzasvir, is progressing as planned, with topline results for the North American C-BEYOND trial anticipated mid-2026 and for the C-FORWARD trial (outside North America) around year-end 2026. Additionally, encouraging preclinical data for AT-587, a potential first-in-class therapy for HEV, support its planned Phase 1 initiation in mid-2026, addressing a critical unmet medical need.

• Atea's global Phase 3 program for chronic HCV infection, comprising the C-BEYOND (North America) and C-FORWARD (outside North America) trials, is on track. The C-BEYOND trial completed enrollment with over 880 patients, with topline results expected mid-2026. The C-FORWARD trial is set to complete enrollment mid-2026, with topline results anticipated around year-end 2026, marking pivotal milestones for the company.
• The fixed-dose combination of bemnifosbuvir and ruzasvir for HCV demonstrated a 98% SVR12 rate in the per-protocol, treatment-adherent population in a Phase 2 study. This regimen offers a differentiated profile with short treatment durations (8 or 12 weeks), once-daily oral dosing, a high barrier to resistance, and a low risk of clinically meaningful drug-drug interactions, including with commonly co-administered proton pump inhibitors and statins.
• Atea is advancing its HEV program with AT-587, a potential first-in-class therapy for which no approved treatments currently exist. Preclinical data presented at CROI 2026 showed AT-587 to be 30- to 150-fold more potent against HEV than sofosbuvir or ribavirin. The company plans to initiate a Phase 1 clinical program for AT-587 in mid-2026, targeting immunocompromised patients at risk of rapid disease progression.

C-BEYOND and C-FORWARD: Pivotal Phase 3 Design for HCV

The clinical trials for hepatitis C virus have evolved significantly over the past two decades, progressing from interferon-based regimens to highly effective direct-acting antiviral (DAA) combinations. The pivotal studies demonstrate a consistent focus on sustained virologic response as the primary efficacy endpoint, with treatment durations ranging from 8-48 weeks depending on the therapeutic regimen and patient population.

Bemnifosbuvir/Ruzasvir's Differentiated Profile in HCV Treatment

The evolution of HCV treatment has progressed from interferon-based regimens with limited efficacy to highly effective direct-acting antivirals (DAAs). Historical standard-of-care treatments achieved modest success rates of 40-70%, while modern DAA regimens consistently demonstrate sustained virological response (SVR) rates exceeding 90% across multiple patient populations.

• Historical peginterferon/ribavirin combinations achieved SVR rates of 50-67% in genotype 1 patients and 84% in genotype 2/3 patients, but were associated with significant adverse events and treatment discontinuations

• First-generation protease inhibitors (telaprevir, boceprevir) combined with peginterferon/ribavirin demonstrated statistically significant improvements over dual therapy alone, including efficacy in treatment-experienced patients, though safety concerns limited their use in advanced liver disease

• Next-generation DAA combinations eliminated the need for interferon while achieving SVR rates of approximately 95%, with pan-genotypic activity, shortened treatment duration, and placebo-like safety profiles even in patients with compensated cirrhosis

• Modern interferon-free regimens consistently achieve SVR12 rates of 93-99% across diverse patient populations, including those with chronic kidney disease (94% with grazoprevir/elbasvir), opioid agonist treatment patients (97.5%), and real-world clinical settings

• Treatment tolerability has dramatically improved from high adverse event rates with peginterferon-based therapy to minimal side effects with current DAAs, enabling successful treatment in previously difficult-to-treat populations and single-visit care models

Addressing Unmet Needs in the Evolving HCV Treatment Landscape

The hepatitis C treatment landscape continues to evolve with highly effective direct-acting antivirals (DAAs) achieving cure rates exceeding 95%. However, significant gaps remain in reaching key populations and addressing systemic barriers that prevent achievement of WHO elimination goals by 2030.

Key Target Populations:

• People who inject drugs (PWID) - identified as the highest priority population requiring enhanced harm reduction strategies and integrated care approaches to reduce transmission and achieve elimination targets

• Marginalized populations including those experiencing homelessness, incarceration, or from HCV-endemic regions who face higher incidence and prevalence but limited access to testing and treatment services

• Children and adolescents - representing an underserved population requiring expanded treatment access and age-appropriate care pathways

• Co-infected patients with HCV/HIV or HCV/HBV, and immunosuppressed populations who experience delayed seroconversion and require specialized management approaches

• Patients with complex medical conditions including those with decompensated cirrhosis, in liver transplantation contexts, or with hepatocellular carcinoma requiring tailored treatment strategies

Critical Unmet Needs:

• Diagnostic and screening gaps - with most infected individuals globally remaining undiagnosed due to inadequate screening infrastructure, poor adherence in high-risk settings (54.5% screening rate in prisons), and delayed detection in immunocompromised populations

• Treatment access barriers - over 70 million people remain untreated globally, with only 12% of diagnosed individuals in some regions receiving treatment, disproportionately affecting low- and middle-income countries

• Provider capacity limitations - 71% of healthcare providers refer patients rather than treating directly due to knowledge deficits (64% of non-treating providers), limited experience, and perceptions that HCV treatment exceeds their scope of practice

• Health system integration challenges - need for decentralized, one-stop services at harm reduction sites, detention facilities, and primary care settings with point-of-care testing and treatment capabilities

• Financial and policy obstacles - including prior authorization requirements, treatment limitations, drug cost burden (cited by 22.8% of untreated individuals), and inadequate sustainable financing for comprehensive programs

• COVID-19 pandemic impact - significant disruption to community and facility-based testing, treatment initiation, and monitoring services, projected to delay elimination goals and requiring adaptive service delivery models

Atea's Dual Antiviral Push: Advancing HCV and HEV Therapies

Atea Pharmaceuticals' latest business update signals a strategic push in antiviral therapeutics, with significant advancements in both Hepatitis C Virus (HCV) and Hepatitis E Virus (HEV) programs. The company's global Phase 3 program for HCV, evaluating the fixed-dose combination of bemnifosbuvir and ruzasvir, is nearing critical data readouts. This combination holds considerable promise, as bemnifosbuvir, a novel NS5B polymerase inhibitor, has demonstrated potent pan-genotypic activity, reportedly 10-fold greater than sofosbuvir in vitro, with a favorable safety profile. Ruzasvir, a potent NS5A inhibitor, complements this, with preclinical studies showing synergistic antiviral activity. If successful, this regimen could offer a highly effective, simplified, and potentially shorter treatment option, aiming to optimize cure rates across diverse HCV genotypes and patient populations.

However, the path forward is not without considerations. Previous two-drug regimens involving ruzasvir have shown suboptimal efficacy in HCV genotype 3 infections, even at higher doses, a factor that will be closely watched in the ongoing Phase 3 trials. Furthermore, clinical studies have identified potential pharmacokinetic interactions between bemnifosbuvir and ruzasvir, where coadministration altered exposure levels of both drugs. While no serious adverse events were reported, this interaction may require careful dose optimization to ensure consistent efficacy and safety. The known susceptibility of NS5A inhibitors like ruzasvir to resistance-associated substitutions also presents a long-term consideration for treatment durability.

Beyond HCV, Atea is making strides in HEV with AT-587, a potential first-in-class therapy. This program is underpinned by preclinical data demonstrating bemnifosbuvir's efficient suppression of HEV replication in vitro and in vivo, including an additive effect with ribavirin and reduced concerns about rapid resistance. HEV represents a critical unmet medical need, particularly for immunocompromised patients who are at high risk of chronic infection and severe liver disease, where current off-label treatments are often inadequate. The planned Phase 1 initiation for AT-587 positions Atea to address this significant gap, leveraging a core asset for a novel indication. This dual-pronged strategy, advancing a late-stage HCV candidate and a promising early-stage HEV therapy, underscores Atea's commitment to diversifying its antiviral pipeline and addressing challenging viral diseases.